source
- Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class. The announcement follows a spate of recent clini…Endpoints · 2mo ago↗ source
- FDA approves AstraZeneca’s baxdrostat for certain patients with hypertensionOne of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday. The blood ...Endpoints · 2mo ago↗ source
- Unlocking more value from mature drug products through strategic outsourcingSee how strategic outsourcing can maximize value and reduce costs for mature drug portfolios.BioPharma Dive